Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)
Antoaneta Tomova, Rupert Bartsch, Thomas Brodowicz et al. · Breast Cancer Research and Treatment · 2009
Cited by 17 works. doi:10.1007/s10549-009-0553-4
Authors
- Antoaneta Tomova
- Rupert Bartsch
- Thomas Brodowicz
- Valentina Tzekova
- Constanta V. Timcheva
- Christoph Wiltschke
- Dany Abi Gerges
- Jan Pawlega
- Stanislav Spanik
- Moshe Inbar
- Christoph Carl Zielinski
References
- Cancer Statistics, 2006
- Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
- Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193)
- A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
- Extending Survival with Chemotherapy in Metastatic Breast Cancer
- Gemcitabine: current status of phase I and II trials.
- Evolving concepts in the systemic drug therapy of breast cancer.